By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AbbVie 

1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


SEARCH JOBS

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries.


Key Statistics


Email:
Ownership: Public

Web Site: AbbVie
Employees:
Symbol: ABBV
 



Industry
Pharmaceutical






Company News
Bristol-Myers Squibb (BMY) and AbbVie (ABBV) Release: FDA Accepts For Priority Review The Biologics License Application For Empliciti (Elotuzumab) For The Treatment Of Multiple Myeloma In Patients Who Have Received One Or More Prior Therapies 9/1/2015 10:19:34 AM
AbbVie (ABBV) Forks Over $350 Million Cash to United Therapeutics (UTHR) for Rare Pediatric Disease Priority Voucher 8/19/2015 6:18:43 AM
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study 8/12/2015 7:53:43 AM
AbbVie (ABBV) Release: Phase 2 Study Of Venetoclax In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia With 17p Deletion Meets Primary Endpoint 8/12/2015 6:55:34 AM
Allergan (AGN) Could Set its Sights on Another Transformative M&A Deal With Biogen (BIIB), Amgen (AMGN) or AbbVie (ABBV) 7/28/2015 7:25:12 AM
AbbVie (ABBV) Reports Second-Quarter 2015 Financial Results 7/24/2015 10:36:16 AM
C2N And AbbVie (ABBV) Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 7/17/2015 6:17:37 AM
Shire (SHPGY): Life One Year After a $54 Billion Takeover Collapse by AbbVie (ABBV) and Its Push Into Biotech 7/14/2015 6:43:02 AM
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Now Approved To Treat Waldenstrom's Macroglobulinemia In Europe 7/10/2015 6:10:35 AM
EXCLUSIVE: New Report Says Biosimilars Will Earn $55B by 2020, As Pfizer (PFE), Actavis (ACT), AbbVie (ABBV) Claim U.S. Market 7/7/2015 1:18:12 PM
12345678910...
//-->